Q-omics provides the consensus-scored TPBGL profile across patient tissues and cancer cell-line models. TPBGL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TPBGL is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TPBGL RNA expression shows 14,968 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRP, KIRC, and PAAD as cancer lineages where TPBGL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPBGL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPBGL survival associations across molecular data types. TPBGL RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPBGL RNA expression–survival associations across cancer types. High TPBGL expression shows unfavorable associations in KIRP, UVM, KIRC, ACC and LUSC, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TPBGL RNA expression.
This table summarizes TPBGL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TPBGL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPBGL shows higher tumor expression in KIRC, HNSC, LIHC, BRCA, STAD and CHOL. The KIRC box plot shows higher TPBGL RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with TPBGL in patient tissues and cancer cell lines. In patient samples, TPBGL shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TPBGL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
